Lifesci Capital reaffirmed their outperform rating on shares of Inhibrx (NASDAQ:INBX – Free Report) in a research report released on Tuesday morning, PriceTargets.com reports. Lifesci Capital also issued estimates for Inhibrx’s FY2023 earnings at ($3.99) EPS.
Inhibrx Trading Up 0.3 %
Shares of NASDAQ:INBX opened at $15.95 on Tuesday. Inhibrx has a 12-month low of $12.60 and a 12-month high of $34.72. The stock has a market cap of $696.54 million, a PE ratio of -3.95 and a beta of 2.71. The business has a 50 day moving average of $24.02 and a 200-day moving average of $23.17. The company has a quick ratio of 7.47, a current ratio of 6.49 and a debt-to-equity ratio of 13.61.
Institutional Investors Weigh In On Inhibrx
Several institutional investors have recently made changes to their positions in the stock. New York State Common Retirement Fund boosted its stake in shares of Inhibrx by 2.2% in the first quarter. New York State Common Retirement Fund now owns 20,580 shares of the company’s stock valued at $388,000 after buying an additional 440 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Inhibrx by 3.0% in the fourth quarter. MetLife Investment Management LLC now owns 17,746 shares of the company’s stock valued at $437,000 after buying an additional 519 shares during the period. Squarepoint Ops LLC raised its position in Inhibrx by 5.0% during the fourth quarter. Squarepoint Ops LLC now owns 15,299 shares of the company’s stock valued at $377,000 after purchasing an additional 732 shares in the last quarter. Voya Investment Management LLC raised its position in Inhibrx by 6.7% during the fourth quarter. Voya Investment Management LLC now owns 12,557 shares of the company’s stock valued at $309,000 after purchasing an additional 784 shares in the last quarter. Finally, American International Group Inc. raised its position in Inhibrx by 5.1% during the second quarter. American International Group Inc. now owns 16,530 shares of the company’s stock valued at $429,000 after purchasing an additional 806 shares in the last quarter. 84.01% of the stock is currently owned by institutional investors.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
- Five stocks we like better than Inhibrx
- Learn Technical Analysis Skills to Master the Stock Market
- Investing in Coffee: 3 Great Strategies to Consider
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 5 Best Stocks to Buy in a Bear Market
- Comparing and Trading High PE Ratio Stocks
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
